Academy of Medical Sciences (United Kingdom)

Dr. Christian Brander and Dr. Mala Maini Join World-class Scientific Advisory Board of AstriVax

Retrieved on: 
星期二, 八月 22, 2023
Vaccine, University College London, Tissue, Myelocyte, UCL, Hepatitis, Immunology, Doctor of Philosophy, HIV, SARS-CoV-2, Medicine, Wellcome Trust, Los Alamos National Laboratory, ICREA, Immunity, Hepatitis B, NK, Infection, Academy of Medical Sciences (United Kingdom), Liver cancer, MD, Transplant, Catalan Institute of Nanoscience and Nanotechnology (ICN2), Viral, Catalan Institution for Research and Advanced Studies, Research, Therapy, Viral hepatitis, Pharmaceutical industry

Together with the other distinguished vaccine development experts on the company’s scientific advisory board, they will support AstriVax in advancing its innovative plug-and-play vaccine platform.

Key Points: 
  • Together with the other distinguished vaccine development experts on the company’s scientific advisory board, they will support AstriVax in advancing its innovative plug-and-play vaccine platform.
  • Leuven, Belgium, August 21, 2023 – AstriVax is pleased to announce that Dr. Christian Brander and Dr. Mala Maini have agreed to join the company’s scientific advisory board.
  • Hanne Callewaert, Ph.D., co-founder and CEO of AstriVax, said: “I am grateful that Christian and Mala have agreed to join our scientific advisory board.
  • I’m also thrilled to have award-winning viral immunologist Mala Maini on board, as her work on hepatitis B and her expertise on improving immunotherapeutic outcomes are invaluable to AstriVax.

Professor Andrew L. Hopkins elected Fellow of the Academy of Medical Sciences

Retrieved on: 
星期四, 五月 18, 2023
Oncology, Health, Technology, General Health, Research, Artificial Intelligence, Science, University of Oxford, Pfizer, University, Translation (biology), Life, Medicine, Society, Biomedical Research, Academy of Medical Sciences (United Kingdom), Translation, National academy, Publishing, Digital health, Patient, Machine learning, Biophysics, School of Life Sciences (University of Dundee), Algorithm, Informatics, Fellows, United, Royal Society, Pharmaceutical industry

Professor Andrew Hopkins FRS FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the Academy of Medical Sciences, one of the United Kingdom’s four National Academies.

Key Points: 
  • Professor Andrew Hopkins FRS FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the Academy of Medical Sciences, one of the United Kingdom’s four National Academies.
  • Both honours reflect Andrew’s life-long passion for harnessing the power of innovative technologies to discover and develop high-quality medicines to benefit patients.
  • As CEO of Exscientia, Andrew led the group who discovered the first AI-designed drugs to enter human clinical trials.
  • “I’m humbled by being elected to join Britain’s and the world’s most distinguished pioneers in medical sciences at the Academy.

Tom Fleming joins first UK-wide Young Academy

Retrieved on: 
星期二, 一月 10, 2023
Other Communications, Consulting, Communications, Professional Services, Biotechnology, Other Health, Health, Pharmaceutical, Other Professional Services, Entrepreneurship, Royal Society, Society, Royal, Global Young Academy, Royal Irish Academy, Knowledge, Medicine, Royal Society of Edinburgh, Policy, Academy of Medical Sciences (United Kingdom), Learned Society of Wales, Multimedia, Private sector, Royal Academy of Engineering, Hatmaking, British Academy

View the full release here: https://www.businesswire.com/news/home/20230110005642/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230110005642/en/
    Arctoris' Co-Founder and COO, Tom Fleming, joins first UK-wide Young Academy (Photo: Business Wire)
    As part of the first cohort of 67 members, announced today (10 Jan) by UK and Ireland National Academies, Tom will have the opportunity to help shape the strategy and focus of this new organisation, based on areas that matter to them.
  • The UK Young Academy has been established as an interdisciplinary collaboration with prestigious national academies: the Academy of Medical Sciences, British Academy, Learned Society of Wales, Royal Academy of Engineering, Royal Irish Academy, Royal Society of Edinburgh, and the Royal Society.
  • It joins the global initiative of Young Academies, with the UK Young Academy becoming the 50th to join the Young Academy movement.
  • Dr Martin-Immanuel Bittner, Co-Founder & CEO of Arctoris and member of the Die Junge Akademie of Germany said: “We are proud to support Tom in his appointment to the newly formed UK Young Academy.

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors

Retrieved on: 
星期一, 一月 9, 2023
CRUK, Roche, Sanofi, SVP, University, London Business School, Therapy, Chemical engineering, New product development, Master of Science, Northwestern University, Biomedical Research, Biopharmaceutical, Berkeley, Medicine, Senior, Drug development, ReNeuron, Academy of Medical Sciences (United Kingdom), CSO, BS, University of Oxford, SABS, Acquisition, European, MBA, Doctor of Philosophy, GSK, Venture capital, BioMarin Pharmaceutical, University of Cambridge, Management, Fine chemical, Pharma, Biotechnology, Asota avacta

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.

Key Points: 
  • LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.
  • Dr Owen is also an advisor to several Venture Capital LPs and is Chairman of Avacta plc’s SABs.
  • Prior to board services, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company recently acquired by Sanofi.
  • Prior to Tizona, Mr Clark was the Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche.

The Lancet: Disparities in life expectancy persist among racial and ethnic groups across the US

Retrieved on: 
星期五, 六月 17, 2022
American Indians, Article, Time, National Center for Health Statistics, Population, NVSS, Centers for Disease Control and Prevention timeline, Mortality, Smoking, COVID-19, Obesity, Alaska Natives, Academy of Medical Sciences (United Kingdom), 2009 Davis Cup, National Institute on Minority Health and Health Disparities, Map, Death, Institute for Health Metrics and Evaluation, Feedback, Institute, Life expectancy, University Place, Washington, Data visualization, Research, NCHS, API, Manuscript, National Vital Statistics System, Hypertension, University, Policy, Health, Sex, IHME, Medical statistics, Communication, Academy, Medicine, Multimedia, American, Diabetes, Use-centered design, Risk, Tutoring, Road, Pharmaceutical industry, Medical device, Oil, Lancet, Evaluation, AIAN, Black, White

New study offers the first comprehensive, county-level life expectancy estimates in the US and highlights important differences among racial and ethnic groups.

Key Points: 
  • New study offers the first comprehensive, county-level life expectancy estimates in the US and highlights important differences among racial and ethnic groups.
  • The analysis reveals that despite overall life expectancy gains of 2.3 years (from 76.8 years in 2000 to 79.1 years in 2019) during the 20-year study period (20002019), disparities among racial and ethnic groups remain, with Black populations still experiencing shorter life expectancy than White populations.
  • "Gains in life expectancy are noteworthy but stop short of suggesting we're closing the gap that persists among different racial and ethnic groups.
  • The study's results highlight considerable variation in life expectancy among racial and ethnic groups, locations, and over time, exposing both positive and negative trends.

MiNA Therapeutics Appoints Two Independent Directors With Extensive Industry Experience to Support Next Phase of Growth

Retrieved on: 
星期二, 十二月 21, 2021
Biotechnology, General Health, Pharmaceutical, Health, Technology, Biostatistics, RNA activation, Therapy, Oxford Sciences Innovation, Leadership, Hospital, Mina, Biomedical Research, Lists of diseases, Head, Inflammation, Equity capital markets, Biotechnology, Cell, Chelsea, Chelsea and Westminster Hospital NHS Foundation Trust, Science, Kingdom, Westminster Hospital, Transplant, Autoimmunity, UK Council for Child Internet Safety, Academy, Health, Independent director, Laboratory, RNA, Cancer, Independent, Patient, Growth, Academy of Medical Sciences (United Kingdom), Member, Imperial College London, Pharmaceutical industry, Management, Medicine

In addition, Susan is a member of the Innovation Advisory Group for the Chelsea and Westminster Hospital NHS Foundation Trust.

Key Points: 
  • In addition, Susan is a member of the Innovation Advisory Group for the Chelsea and Westminster Hospital NHS Foundation Trust.
  • Susan Clement-Davies, Independent Director of MiNA Therapeutics, commented:
    I am extremely excited to be joining MiNA.
  • Professor Sir Robert Lechler, Independent Director of MiNA Therapeutics, commented:
    This is a fantastic opportunity to be involved with a pioneering company in such an interesting space.
  • MiNA Therapeutics is the leader in small activating RNA therapeutics.

CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors

Retrieved on: 
星期一, 十月 4, 2021
UCSF, Therapy, Medicine, Â, Susan, BRCA2, Royal Society, University, Cancer Research UK, SAN, Safety, Tumor microenvironment, Breast cancer, PARP, Academy, Technology, Biotechnology, Research, Academy of Medical Sciences (United Kingdom), LinkedIn, CD166, Twitter, Bristol Myers Squibb, Royal, Imperial College London, FRS, European Molecular Biology Organization, United, Biochemistry, Clinical trial, Breast, Neoplasm, Oncology, Samuel, Cancer, Institute, The Genetics Society, Toxicity, Company, European Society for Medical Oncology, Risk, University College London, Drug discovery, GLOBE, University of California, ADP, CD71, Doctor of Philosophy, Patient, University of London, Chemistry, COVID-19, AbbVie, Nasdaq, Meyenburg, Pharmaceutical industry, Management

It is a privilege to welcome Alan to our board, commented Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics.

Key Points: 
  • It is a privilege to welcome Alan to our board, commented Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics.
  • It is my pleasure to join CytomXs board as the Company continues to innovate and advance its broad and diverse pipeline of potential first-in-class product candidates, said Dr. Ashworth.
  • I look forward to working with the entire board and the executive team to help advance CytomXs vision of bringing more effective therapies to cancer patients.
  • For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter .

Dr. Sarah Teichmann FmedCci FRS Joins Transition Bio as Scientific Co-Founder

Retrieved on: 
星期三, 九月 22, 2021
Technology, Biotechnology, Nanotechnology, Health, Pharmaceutical, Oncology, Other Science, Research, Software, General Health, Genetics, Science, Data Management, Clinical Trials, Biophysics, Biochemical Society, Distinguished Fellow of the British Computer Society, Artificial intelligence, Research, Computational biology, Wellcome Sanger Institute, Harvard University, OC, EMBO, Medicine, Teichmann, Therapy, Health, Yusuf Hamied Department of Chemistry, Mallinckrodt, Map, Research fellow, Cavendish Laboratory, Physical chemistry, Academy of Medical Sciences (United Kingdom), Laboratory, Gold medal, Fellow, International Society, Biology, Drug design, Genomics, University, Royal Society, Company, EMBO Gold Medal, Disease, Technology, Algorithm, Science, FRCP, Applied physics, Royal, Churchill College, Cambridge, Drug discovery, Transition, Department, FRS, FRSC, Machine learning, Physics, Academy, Management, Pharmaceutical industry

Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.

Key Points: 
  • Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.
  • Dr. Samuel Cohen, a former research fellow in Biophysical Chemistry at the University of Cambridge and visiting fellow at Harvard University, is also a Founder of the Company.
  • Martin commented further, From a scientific leadership and breakthrough innovation standpoint, the combination of our scientific team of doctors Weitz, Knowles, Hyslop, and now Teichmann is as good as it could possibly get.
  • Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis.

Lingnan University study finds air pollution levels of incense-burning temples far exceeds air quality standards

Retrieved on: 
星期五, 九月 10, 2021

HONG KONG, Sept. 10, 2021 /PRNewswire/ -- A recent study conducted by the Science Unit of Lingnan University in Hong Kong (LU) shows that concentrations of fine particulate matter (PM2.5) from incense burning both inside and outside temples could be 6 times and 4 times of the  recommended levels respectively. In addition, the more temples there are in the same district, the higher the respiratory mortality rate. The research team suggests that alternative measures, such as installation of automatic mist sprayers to reduce smoke dispersion, as well as using incense made with non-toxic substances to minimise health risks to worshippers and neighbours, should be considered.

Key Points: 
  • In addition, the more temples there are in the same district, the higher the respiratory mortality rate.
  • Over 70 per cent of registered Chinese temples in Hong Kong are in urban areas close to residential and commercial districts, and air pollution from burning incense may have a negative impact on the local communities.
  • Results suggest that incense burning in temples is a main factor in air pollution, and the more temples located in the same district, the higher the reported rate of respiratory mortality.
  • For residents nearby, they should close all windows facing the temple during incense burning, clean air conditioner filters regularly, and consider using air purifiers to improve the air quality of their home.

Lingnan University study finds air pollution levels of incense-burning temples far exceeds air quality standards

Retrieved on: 
星期五, 九月 10, 2021

HONG KONG, Sept. 10, 2021 /PRNewswire/ -- A recent study conducted by the Science Unit of Lingnan University in Hong Kong (LU) shows that concentrations of fine particulate matter (PM2.5) from incense burning both inside and outside temples could be 6 times and 4 times of the  recommended levels respectively. In addition, the more temples there are in the same district, the higher the respiratory mortality rate. The research team suggests that alternative measures, such as installation of automatic mist sprayers to reduce smoke dispersion, as well as using incense made with non-toxic substances to minimise health risks to worshippers and neighbours, should be considered.

Key Points: 
  • In addition, the more temples there are in the same district, the higher the respiratory mortality rate.
  • Over 70 per cent of registered Chinese temples in Hong Kong are in urban areas close to residential and commercial districts, and air pollution from burning incense may have a negative impact on the local communities.
  • Results suggest that incense burning in temples is a main factor in air pollution, and the more temples located in the same district, the higher the reported rate of respiratory mortality.
  • For residents nearby, they should close all windows facing the temple during incense burning, clean air conditioner filters regularly, and consider using air purifiers to improve the air quality of their home.